177lu-psma-eb-01
Peptideexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 23, 2022 (NCT05613738)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Glutamate carboxypeptidase IIRadiopharmaceutical
FOLH1 radiopharmaceutical
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06237491 | Phase 1 | May 7, 2025 | Yantai LNC Biotechnology Singapore PTE. LTD. |
| NCT05613738 | N/A | Nov 23, 2022 | Chinese Academy of Medical Sciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Yantai LNC Biotechnology Singapore PTE. LTD. | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1